Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Morphine × Head & Neck × Clear all

Phase

Phase 4 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6 Other 1 Head & Neck 1 CNS 1

Conditions

Head and Neck Neoplasms 1 Breakthrough Pain 1

Interventions

Cisplatin 5 lenvatinib 4 Fluorouracil 3 Fentanyl 3 Docetaxel 3 trametinib 2 selpercatinib 2 pralsetinib 2 pembrolizumab 2 nimotuzumab 2 larotrectinib 2 dabrafenib 2 cabozantinib 2 anlotinib 2 Thyrotropin Alfa 2 Saline Solution 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Norepinephrine 2 Metformin 2 Indocyanine Green 2 Cinacalcet 2 Cetuximab 2 Carboplatin 2 xiaojin wan 1 vandetanib 1 toripalimab 1 technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1 technetium Tc 99m nanocolloid 1 sintilimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02869321 2019-05-13

ANTALGIP

Central Hospital, Nancy, France

Phase 4 Completed

Head and Neck Neoplasms, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡